Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas

Modern Pathology

Volumn 28, Issue 3, 2015, Pages 391-402

  Waser, Beatrice ^a   Blank, Annika ^a   Karamitopoulou, Eva ^a   Perren, Aurel ^a   Reubi, Jean C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; SOMATOSTATIN; GLP1R PROTEIN, HUMAN; GLUCAGON RECEPTOR;

ARTICLE; AUTORADIOGRAPHY; CHRONIC PANCREATITIS; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; INSULINOMA; LIVER HYPERPLASIA; MAJOR CLINICAL STUDY; PANCREAS CARCINOMA; PANCREAS DUCT; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; WESTERN BLOTTING; BIOSYNTHESIS; METABOLISM; PANCREAS; PANCREAS TUMOR; THYROID DISEASE; THYROID GLAND; THYROID TUMOR;

AUTORADIOGRAPHY; BLOTTING, WESTERN; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; IMMUNOHISTOCHEMISTRY; PANCREAS; PANCREATIC NEOPLASMS; RECEPTORS, GLUCAGON; THYROID DISEASES; THYROID GLAND; THYROID NEOPLASMS;

EID: 84938414413     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.113     Document Type: Article

References (29)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439
2. Körner M, Stockli M, Waser B, et al. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007;48:736-743
3. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors as molecular basis for in vivo multireceptor tumor targeting. Eur J Nucl Med 2003;30:781-793
4. Holst JJ, Vilsboll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009;297:127-136
5. Drucker DJ, Dritselis A, Kirkpatrick P. Liraglutide. Nat Rev Drug Discov 2010;9:267-268
6. Drucker DJ, Nauck MA. The incretin system: glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-inhibitors in type 2 diabetes. Lancet 2006;368: 1696-1705
7. Wild D, Mäcke H, Christ E, et al. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N Engl J Med 2008;359:766-768
8. Christ E, Wild D, Ederer S, et al. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol 2013;1:115-122
9. Sowa-Staszczak A, Pach D, Mikolajczak R, et al. Glucagon-like peptide-1 receptor imaging with [Lys40 (Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 2013;40:524-531
10. Boerman OC, Gotthardt M. 18F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster? Eur J Nucl Med Mol Imaging 2012;39: 461-462
11. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 2013;62:3316-3323
12. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-156
13. Nauck MA, Friedrich N. Do GLP-1-based therapies increase cancer risk? Diabetes Care 2013;36(Suppl 2): S245-S252
14. Victozas (liraglutide injection) Human Relevance of Rodent Thyroid C-cell Tumors. http://www.fda.gov/ downloads/AdvisoryCommittees/Committees%20 MeetingMaterials/Drugs/EndocrinologicandMetabolic-DrugsAdvisoryCommittee/UCM151129.pdf; Accessed October 2010
15. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-1486
16. Boess F, Bertinetti-Lapatki C, Zoffmann S, et al. Effect of GLP1R agonists taspoglutide and liraglutide on primary thyroid C-cells from rodent and man. J Mol Endocrinol 2013;50:325-336
17. Butler AE, Campbell-Thompson M, Gurlo T, et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604
18. Butler PC, Elashoff M, Elashoff R, et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36: 2118-2125
19. Gale EA. GLP-1-based therapies and the exocrine pancreas: more light, or just more heat? Diabetes 2012; 61:986-988
20. Kahn SE. Incretin therapy and islet pathology: a time for caution. Diabetes 2013;62:2178-2180
21. Waser B, Beetschen K, Pellegata NS, et al. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretinbased diabetes therapy. Neuroendocrinology 2011;94: 291-301
22. Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-receptor expression in the human thyroid gland. J Clin Endocrinol Metab 2012;97:121-131
23. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor-or not? Endocrinology 2013;154:4-8
24. Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue; novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 2014;155:1280-1290
25. Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 2012;61:1250-1262
26. Wild D, Caplin M, Christ E, et al. Glucagonlike peptide-1 vs. somatostatin receptor targeting in malignant insulinomas. J Nucl Med 2011;52: 1073-1078
27. Körner M, Waser B, Schonbrunn A, et al. Somatostatin receptors subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting. Am J Surg Pathol 2012;36:242-252
28. Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2013;34:676-688
29. Nakamura T, Ito T, Uchida M, et al. PSCs and GLP-1R: occurrence in normal pancreas, acute/chronic pancreatitis and effect of their activation by a GLP-1R agonist. Lab Invest 2014;94:63-78.